A Phase III study of Pomalidomide and low dose Dexamethasone with or without Pembrolizumab (MK-3475) in refractory or relapsed and refractory Multiple Myeloma (rrMM)
The goal of this optional sub-study is to collect new blood samples and leftover blood and/or tissue samples for use in future research related to cancer. This research may include genetic research, biomarker testing (which may include genetic biomarkers), and pharmacogenetic (PGt) testing. PGt testing looks at how someone's genes may influence how they respond to chemotherapy drugs. They are different from genetic testing done to diagnose you with a genetic disease or find out your risk of having a genetic disease. Biomarkers are found in the blood and tissue and may be related to your reaction to the study drugs.
Treatment Location: N/A
IRB Review and Approval Date: 05/19/2016
Recruitment Status: Closed
Projected Accrual: N/A
Information and next steps
For general questions about clinical trials: